Pseudomonas aeruginosa is one of the most clinically threatening and drug-resistant pathogens, ranking second among the 12 superbugs most urgently in need of antimicrobials (World Health Organization, 2017). In 2022, more than 420,818 cases of P. aeruginosa infections were detected in Chinese medical institutions, with a 16.6% drug resistance rate to carbapenems (CRPA).

The phage library of P. aeruginosa at CreatiPhage is characterized by high quality, comprehensive information, and broad intra-specie coverage. Therefore, CPD-PA01 is a natural phage cocktail that broadly targets clinically prevalent strains of drug-resistant P. aeruginosa. It is in liquid form and indicated for wound infections. Currently, the initial animal safety verification has been completed, and we are collaborating with partner hospital to apply for a controlled clinical trial (investigate-initiated trial).

Acinetobacter baumannii accounts for over 400,000 related deaths annually worldwide, ranking first among 12 superbugs (World Health Organization, 2017). In China, 220,000 cases of Acinetobacter baumannii infections were detected in healthcare facilities in 2020, 53.7% of which were resistant to carbapenem antibiotics (CRAB), with no new antibiotics available. 

CreatiPhage’s Acinetobacter baumannii phage library is of high quality, with comprehensive information and wide strain coverage. The BroadPhage™Acinetobacter baumannii, a natural phage cocktail covering drug-resistant strains, is currently undergoing Phase I innovative biological medicine preclinical studies. The initial pipeline is indicated for lug infections, with the phage formulation being a liquid administered via nebullization.

Klebsiella pneumoniae is a clinically threatening and highly drug-resistant enterobacteria, with over 600,000 global deaths annually, ranking it third on the World Health Organization's list of 12 major 

superbugs released in 2017. In China, medical institutions detected 482,000 cases of Klebsiella pneumoniae infections in 2020, with a resistance rate to third-generation cephalosporins (CRE) as high as

 31.1% and a resistance rate to carbapenem antibiotics (CRKP) reaching 10.9%.

The core scientists of the CreatiPhage team have been conducting research on phages-Klebsiella pneumoniae for the long term, possessing a high-quality, informatized, and extensively covered phage

 library and genetic manipulation techniques specifically for Klebsiella pneumoniae. The synthetic biology project of Klebsiella pneumoniae has been supported by the Shanghai Pujiang Talent Program and 

the Shanghai Municipal Health Commission project. The Heshi™ Feikang is a gene-editing phage cocktail that covers a broad-spectrum of drug-resistant Klebsiella pneumoniae and is currently in the

 laboratory research and development stage.

Pseudomonas aeruginosa is responsible for over 300,000 global deaths each year, ranking it second on the World Health Organization's list of 12 major superbugs published in 2017. In China, medical 

nstitutions reported 281,000 cases of Pseudomonas aeruginosa infections in 2020, with 18.3% being superbugs resistant to carbapenem antibiotics (CRPA). Due to factors such as the propensity to form 

biofilms, Pseudomonas aeruginosa causes a large number of chronic infections in the lungs, urinary tract, and other areas, leading to poor antibiotic treatment outcomes and an urgent need for new drug 

development.

The core scientists of the Creatiphage team have been engaged in long-term research on phages-Pseudomonas aeruginosa, possessing a high-quality, informatized, and extensively covered phage 

library and genetic manipulation techniques specifically for Pseudomonas aeruginosa. The ongoing research project is supported by the National Key Research and Development Program for Synthetic 

Biology. The Heshi™ Tonglu is a gene-editing phage cocktail that covers a broad-spectrum of drug-resistant Pseudomonas aeruginosa and is currently in the laboratory research and development stage.

The first step in personalized phage therapy and customize services is selecting lytic phages from the target bacteria's corresponding cPhageBank which has a huge future diagnostic market. CreatiPhage has developed the second-generation plaque/killing-curve phage screening technologies (TestiPhi™ Solid/Liquid Screening) and planned the third-generation virtual cPhageBank screening technology (ComputiPhi™ Screening). The second-generation plaque screening method, paired with CreatiPhage's co-developed intelligent identification scoring report system, allows for high-throughput screening of 96 phages per agarplate, using image-based intelligent recognition to lock onto lytic phages for conventional growth-speed clinical bacteria within 8 hours. The liquid screening method can screen 96/384 phages per multi-well plate at high throughput, with an automatic real-time bacterial growth monitoring system for scoring based on phage lytic power and bacterial tolerance, completing the lytic phage identification within 4 hours and lytic plus lower-resistant phage identification within 16 hours. The third-generation virtual cPhageBank screening technology uses data mining and deep learning on the CreatiPhage phage-bacteria interaction phenotype database and sequence database, conducting virtual selection of lytic phages based on the key determinant components in the bacteria-phage sequence.

Currently, CreatiPhage offers phage screening service for institutions or individuals, inviting to follow the WeChat public account (创噬纪CreatiPhage) or contact us for more information. Additionally, the CreatiPhage plans to file the diagnosis series for the first approved medical technology (non-restricted category) with the Shanghai Municipal Health Commission through the construction of its own diagnostic laboratory later.

The ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) are the most common, drug-resistant, and difficult-to-treat pathogens worldwide, causing over 3.2 million related deaths annually, ranking at the top of the WHO's list of 12 superbugs in 2017. In China, 2.168 million cases of ESKAPE infections were monitored in healthcare facilities in 2020. For specific pathogens infected patients, CreatiPhage utilizes its established standard cPhageBank high-throughput phage screening technologies, and phage combination system to quickly select the most suitable personalized phage cocktail formula for treatment. 

Currently, CreatiPhage's cPhageBank treatment technology is being filed with the Shanghai Municipal Health Commission as the first medical technology (restricted category) initiative by cooperating medical institutions. The phage formulation is a liquid, indicated for multiple bacterial species and infection types, with administration methods tailored to the infection site, such as neubulization, bladder irrigation, wet dressing, and catheter flushing.

For the most common, drug-resistant superbugs that are prone to hospital-acquired infections and transmission within human environments such as healthcare facilities, nursing homes, and households, a series of broad-spectrum phage cocktail products targeting clinically prevalent bacterial strains have been developed. This fixed formula product can be dynamically updated based on changes in clinically prevalent strains with product types including environmental improvement agents in liquid, powder, and tablet forms, suitable for healthcare facilities, nursing homes, and home environments with infected or susceptible individuals. 

The PHAGINK™ series’ first pipeline is a fixed formula product targeting targeting clinically prevalent ESKAPE antibiotic-resistant strains, applicable for empirical (non-customized environmental spraying to reduce the risk of transmission of the aforementioned bacteria. Follow our WeChat public account (CreatiPhage), visit our Taobao store (CreatiPhage FeiJin phages), or contact us for more information.

In response to non-dominant bacterial strains and other superbugs that cannot be covered by the PHAGINK™ product in human habitation, animal husbandry, and food processing environments, local bacteria are isolated through environmental sampling. On one hand, based on the corresponding phage library's broad-spectrum compatibility, targeted phages are rapidly screened from the cPhageBank and assembled into a full-coverage, semi-customized cocktail. This cocktail is then used for environmental disinfection through the medical and household sprayers designated by CreatiPhage, specifically targeting and eliminating the target bacteria in the environment. Concurrently, for long-term cooperation, bacterial detection and transmission can be monitored by cPhageBank lysis profile of the isolated bacteria (bacterial typing) at different time points and sampling sites, as well as by sequencing the environmental bacterial community, to enable timely intervention, identify weak links in infection control, and make improvements. This customized service is applicable in scenarios such as medical and health institutions, animal welfare and aquaculture organizations, food processing facilities, as well as human habitations.